InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
InterCure reported record revenue of $150 million for fiscal year 2022, with a gross profit of $61 million and an adjusted EBITDA of $32 million, reflecting a solid 22% of revenues. The net income stood at $17 million, and the company generated $20 million in cash flow from operations, ending the year with a strong cash position of $95 million. In Q4 2022, revenue reached $41 million, marking a 33% year-over-year increase. The company expanded its operations with the addition of 8 medical cannabis dispensaries and launched over 30 new products.
- Record fiscal year 2022 revenue of $150 million, representing growth from $219 million in 2021.
- Adjusted EBITDA increased to $32 million, representing 22% of total revenues.
- Net income reached $17 million, a strong performance.
- Successful global expansion with new dispensary openings in Europe.
- Increased market share driven by demand for Canndoc's products.
- Gross margin decreased to 35% in Q4 2022 from 44% in Q3 2022, impacted by market conditions.
Record fiscal year 2022 revenue of $150 million
Record fiscal year 2022 Adjusted EBITDA* of $32 million
Record fiscal year 2022 net income of $17 million
Generated
Strong balance sheet with over $95 million cash
NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted.
Full Year 2022 Key Financial & Operating Highlights (Cannabis Sector)
- Record fiscal year 2022 revenue of
$150 million (NIS 389 million). - Gross profit of
$61 million (NIS 159 million) and gross margin of41% . - Adjusted EBITDA of
$32 Million (NIS 84 million) representing22% of revenues. - Net income (consolidated) of
$17 million (NIS 44 Million). - Garneted positive (consolidated) cash flow from operations of
$20 Million (NIS 51 Million). - Cash (consolidated) at year end of
$95 million (NIS 246 million). - Increased market share due to solid demand for Canndoc's branded products and expansion of the Company’s medical cannabis dispensing operations.
- Added 8 locations to its leading medical cannabis dedicated pharmacy chain to a total of 28, out of which 20 are actively dispensing medical cannabis.
- Executed our global expansion strategy with the successful opening of the first Cookies flagship store in Vienna, Austria, and adding the first location in London, UK which in the process of obtaining regulatory approvals. (Part of the total 28 location mentioned above)
- Scaled up our cultivation, production facilities and expended our distribution pharmaceutical logistic hub capacity, further solidifying us as one of the largest and most advanced platforms in the space.
- Record of new product launches with more than 30 new GMP SKUs added to the Company's portfolio of products during the quarter.
- First company to comply with the new strict 109 import regulations of the Israel Medical Cannabis Agency, resuming importation of medical cannabis to Israel.
*Cannabis sector
Fourth Quarter Key Financial & Operating Highlights (Cannabis Sector)
- Record revenue of
$4 1 million (NIS 106 million)33% growth YoY and5% QoQ growth due to continued increase in market share. - Gross profit of
$14 million (NIS 37 million), gross margin of35% dropped from44% (QoQ) as a result market condition. During the fourth quarter, financially struggling companies and companies exiting the market sold low-to-medium quality products at lower prices to liquidate their inventories. This had an impact primarily on our ultra-medical and legacy products, while the prices for our top selling high quality products remained stable. - Adjusted EBITDA of
$7 million (NIS 19 million), representing18% of revenues. - Expended our exclusive partnership with Organigram, a world-leading indoor grower, to supply us up to 20 tons and extending its reach into new territories and product lines.
- Announced expansion of the company's partnership forming a collaboration with the renowned cannabis brand 'Binske' to develop and offer a range of non-flower cannabis products, which we believe will significantly enhance our product portfolio and further strengthen our market position.
Post-fourth quarter 2022 Highlights
- Successfully completed export of our GMP products to Intercure's EU hub, preparing for commercial launches of our products in UK and Germany.
- Announced the termination of the Better acquisition agreement, which has led us subsequently to file a lawsuit to recover the funds loaned in connection with the merger agreement.
“We are pleased to report another record-breaking quarter and fiscal year for InterCure, solidifying our leading position," said InterCure CEO Alexander Rabinovich, adding “As our target markets are evolving, we remain focused on execution with financial discipline while navigating through regulatory barriers and market challenges. During 2022, we have successfully ramped up our upstream global supply chain and scaled our downstream distribution operations to meet the solid demand for our high-quality branded products. While favorable regulatory cannabis reforms are on the horizon, we expect our growth journey to continue as we remain focused and committed to expand our leading platform, building shareholder value and improving quality of life for patient communities across the world.”
Key Q4 and Full Year 2022 Financial Highlights – Cannabis Sector
(In thousands NIS)
| 2021 | 2022 | |
| Revenues | 219,677 | 388,684 |
| Gross Profit (1) | 95,989 | 158,957 |
| Adjusted EBITDA (2) | 56,897 | 84,125 |
| Q4-21 | Q4-22 | |
| Revenues | 79,702 | 105,606 |
| Gross Profit (1) | 36,613 | 37,484 |
| Adjusted EBITDA (2) | 21,091 | 18,527 |
| Q2-21 | Q3-21 | Q4-21 | Q1-22 | Q2-22 | Q3-22 | Q4-22 | |
| Revenues | 45,230 | 61,695 | 79,701 | 87,229 | 95,277 | 100,572 | 105,606 |
| Gross Profit (1) | 19,267 | 24,682 | 36,613 | 35,857 | 41,542 | 44,074 | 37,484 |
| Gross Profit % | | | | | | | |
| Adjusted EBITDA(2) | 11,701 | 14,041 | 21,091 | 21,298 | 22,113 | 22,187 | 18,527 |
| Adjusted EBITDA % | | | | | | | |
| (1) | Gross profit before effect of fair value. | |
| (2) | EBITDA adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This is a non-IFRS financial measure and does not have a standardized meaning prescribed by IFRS, please see “Non-IFRS Measures” below. |
Webcast and Conference Call
The Company will conduct a webcast on Monday, April 3, 2023 at 04:30 p.m. (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy.
Participants can access the live webcast and conference call through the following link:
https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca91cdb4a
Consolidated Financial Statements, Management's Discussion and Analysis and Annual Information Form
InterCure's audited financial statements and accompanying notes for the year ended December 31, 2022 and related management's discussion and analysis of financial condition and results of operations ("MD&A"), together with its Annual Information Form for the same period, are available under the Company's profile on SEDAR.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Non-IFRS Measures
This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company. A reconciliation of Adjusted EBITDA to an IFRS measure (revenue), which is incorporated by reference to this press release, is available in InterCure’s MD&A for the period under the heading “Results of Operation”, available under the Company's profile on SEDAR at www.sedar.com.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to InterCure’s objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s future revenue growth and profitability, the success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the war in Ukraine, macro economic factors (including inflation) and uncertainty created as a result of the socio-political situation in Israel. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2022, which is available on SEDAR at www.sedar.com, and under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form 20-F, filed with the Securities Exchange Commission on July 14, 2021, as amended August 3, 2021 and August 18, 2021. InterCure undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Contact:
InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c892f769-b7be-4838-9e15-847c00c73873
FAQ
What were InterCure's earnings for fiscal year 2022?
What is InterCure's adjusted EBITDA for Q4 2022?
How much cash flow from operations did InterCure generate in fiscal year 2022?
What is the current cash position of InterCure?
What is the outlook for InterCure's market share in 2023?
